Project Grant R01AI191494
Award Date 8/11/25
Completion Date 7/31/30
Dollars Obligated $624K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, EE. UU.
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $637,275 to the Texas A&M Engineering Experiment Station (Tees) to conduct research on the role of extant porins in antibiotic tolerance for major pathogenic bacterial species. The proposed work aims to uncover the mechanisms by which gram-negative bacterial pathogens can rapidly adapt their outer...
- This $1,144,714 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research to discover physicochemical traits that allow antibiotics to evade efflux pumps in Gram-negative bacteria. The research aims to identify rules for efflux pump evasion, which could enable the design of highly potent antibiotics across multiple compound classes to address the growing issue of antibiotic...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,120,070 to the University of Oklahoma to develop novel tools and resources for optimizing the intracellular accumulation of antibacterial agents effective against Gram-negative bacteria. The key objectives of this 5-year research project are to: 1) Generate predictive machine learning models for active...
- This $475,036 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research to explore synergistic combinations of aminoglycoside antibiotics against multidrug-resistant (MDR) gram-negative bacteria. The project aims to: 1) examine dual-aminoglycoside combinations against MDR pathogens like Enterobacter cloacae, E. coli, and Klebsiella pneumoniae, 2) solve the structural details of how multiple...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,201,716 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Rector & Visitors of the University of Virginia (UVA). The grant, effective August 6, 2025 through July 31, 2030, aims to develop and apply innovative high-throughput screening platforms to measure the accumulation of small molecules in the multidrug-resistant pathogen Acinetobacter baumannii (A. baumannii)....
- This federal Project Grant award of $451,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to The Trustees of Princeton University supports research to identify new antimicrobial targets in gram-negative bacterial pathogens using chemical synthetic lethality. The key objectives are to: 1) Identify a small molecule inhibitor of methionine synthase, a recently identified essential target in Burkholderia pseudomallei, when...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $254,478 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Southwestern Medical Center to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds and develop strategies to circumvent them. The project aims to determine the resistance mechanisms for lead peptide-phosphorodiamidate morpholino oligomers (PPMOs) against...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $161,859 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Texas A&M University System Health Science Center (TAMU HSC) to conduct research on discovering novel antivirulence drug targets for Clostridioides difficile infection (CDI). The research aims to identify genetic mechanisms that regulate the production of virulence toxins by C. difficile, with the goal of finding...
- This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing while...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $585,539 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to the University of Illinois in Chicago. The grant supports research to understand how the pathogen Acinetobacter baumannii, a major public health threat due to its drug resistance, colonizes and persists in the human gut microbiome. The project aims to investigate A....